Dr Mark Levick is a former EU medicines regulator and CEO of a NASDAQ-listed biopharmaceutical company. Mark’s expertise was gained through leading global R&D groups at GlaxoSmithKline and Novartis in the UK, US and Switzerland. Mark provides scientific advice, due diligence, consulting and board advisory for biotech start-ups, venture capital firms, portfolio companies, pharmaceutical SME's, as well as investor, financial and legal firms. Mark is a partner with Andrew Roberts, MSc MBA in Thaxton Philip Consulting. We work with a network of trusted colleagues to deliver the results you need. 

Mark has a proven track record with 13 global marketing approvals under his belt, including five first-in-class molecules and two approvals arising from successful proof-of-concept programs, which have together created more than $3bn of portfolio value over the past five years alone. Mark's career has focused on developing complex biopharmaceuticals such as monoclonal antibodies, engineered proteins, cell-based therapies, and other novel platforms. Mark's expertise includes translational science, clinical pharmacology, clinical development, technical operations and regulatory affairs. Mark is a qualified executive coach and he can also help senior leadership teams to connect the scientific and people aspects of innovation. 

​

Before joining industry, Mark was a medical reviewer for the UK and EU medicines regulatory authorities and a specialist physician-scientist practising in hospitals in Australia and the UK. Mark earned his medical degree from the University of Newcastle, Australia, and he holds a PhD in vaccine development from the University of Cambridge. Mark has received several awards and authored peer-reviewed papers in the fields of vaccine and drug development. Mark is a Fellow of the Royal College of Pathologists of Australasia and affiliated with the Faculty of Pharmaceutical Medicine in the Royal College of Physicians.